Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical ABI-1968 in cHSIL
NCT03239223Phase 1Completed
- Sponsor
- Antiva Biosciences
- Start
- Jan 2018
- Primary completion
- Oct 2018
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of abi-1968 in Squamous Intraepithelial Lesion (SIL) (2 arms), sponsored by Antiva Biosciences. Primary endpoint: Maximum Tolerated Dose at 85 Days. Started Jan 2018; status: completed.
02
Drugs
abi-1968
03
Conditions
Squamous Intraepithelial Lesion (SIL)
Beyond the preview
Go deeper on NCT03239223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239223.